« Return to News | CROs/Service Providers

2006 Is Strong Year For Averion Despite Merger Costs

Monday, April 9, 2007 01:11 PM

Boston-based CRO Averion International reported a 48% increase in revenue for 2006 to $27.3 million. However, the company reported a loss in net operating income of $9.2 million, primarily due to costs associated with a merger in 2005 with Millennix and a 2006 reverse merger with IT&E International. The company’s chief executive officer Philip Lavin stated the Averion has had a “solid start” during the first quarter of 2007 and its goal is to reach profitability by the second of half of the year. Averion's backlog of business within clinical research was $35.6 million as of December 31, 2006. Cash and equivalents were roughly  $8.1 million, an increase of $1.7 million from 2005.

In February, Averion completed cost reduction initiatives, which included cutting 13% of its staff. The cuts are expected to reduce operating costs by $2.5 million a year. Averion's backlog of business within clinical research was $35.6 million as of December 31, 2006. Cash and equivalents were roughly $8.1 million, an increase of $1.7 million from 2005. The company stated it had executed a record high of $13.1 million in newly signed contracts during Q1 2007.

“Our clients have confidence in our ability to deliver. We are building on this foundation by capitalizing on additional synergistic opportunities afforded by our recent transactions, as well as on market trends that are supporting our industry's rapid growth,” said Lavin.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.